The funding will primarily be allocated toward the submission of an application to British regulators to allow for the ...

Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform.

Qnovia has received clearance from the US Food and Drug Administration (FDA) to start a clinical trial for its RespiRX ...

Qnovia, Inc., a pharmaceutical company who recently announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the RespiRx™ Nicotine ...

Qnovia, a Richmond startup focused on smoking-cessation technology, has raised $16 million in a Series B round.

In conclusion, NRT (nicotine gum or inhaler) doubled the quit rate compared ... 46.6 ± 10.0 (20–67) Age started smoking (years) 18.3 ± 3.3 (8–30) 18.6 ± 3.9 (12–42) Cigarettes smoked ...

Inhaler: peak plasma concentrations of 49ng ... Nasal Spray antagonized by nasal vasoconstrictors (eg, xylometazoline). Smoking cessation potentiates theophylline, insulin, β-blockers ...

Aerosol delivery devices are hand-held, portable drug delivery devices. They consist of suspension of solid or liquid particles in a carrier gas, which makes feasible for treatment of respiratory and ...

Smoking causes lung disease ... Relievers are often administered using a device called an inhaler. This lets you breathe the medicine in through your mouth and directly into your lungs.

Protect your lungs this winter! Tips for asthma, COPD, & other respiratory conditions. Learn how to stay healthy & avoid ...